FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 244 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial... September 25, 2024 FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... May 13, 2026 BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... April 4, 2022 Why haven’t we cured cancer? – That Cancer Conversation June 14, 2022 Load more HOT NEWS Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer What Are Multi-Cancer Early Detection Tests and How Might They Impact... FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene...
